| [1] |
|
| [2] |
Mort RL, Jackson IJ, Patton EE. The melanocyte lineage in development and disease[J]. Development, 2015, 142(4): 620-632. DOI: 10.1242/dev.106567.
|
| [3] |
Jamaer E, Liang Z, Stagg B. Primary malignant melanoma of the vagina[J]. BMJ Case Rep, 2020, 13: e232200. DOI: 10.1136/bcr-2019-232200.
|
| [4] |
Kalampokas E, Kalampokas T, Damaskos C. Primary vaginal melanoma, a rare and aggressive entity. A case report and review of the literature[J]. In Vivo, 2017, 31: 133-139. DOI: 10.21873/invivo.11036.
|
| [5] |
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology—Melanoma: cutaneous, version 1.2021[EB/OL]. (2021-02-19)[2021-08-19].
URL
|
| [6] |
|
| [7] |
Shoushtari AN, Wagstaff J, Ascierto PA, et al. CheckMate 067: long-term outcomes in patients with mucosal melanoma[J]. J Clin Oncol, 2020, 38(15_suppl): 10019. DOI: 10.1200/JCO.2020.38.15_suppl.10019.
|
| [8] |
Gutzmer R, Stroyakovskiy D, Gogas H, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2020, 395(10240): 1835-1844. DOI: 10.1016/S0140-6736(20)30934-X.
|
| [9] |
Lian B, Si L, Cui C, et al. Phase Ⅱ randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma[J]. Clin Cancer Res, 2013, 19(16): 4488-4498. DOI: 10.1158/1078-0432.CCR-13-0739.
|
| [10] |
Eggermont A, Suciu S, Testori A, et al. Long-term results of the randomized phase Ⅲ trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage Ⅲ melanoma[J]. J Clin Oncol, 2012, 30(31): 3810-3818. DOI: 10.1200/JCO.2011.41.3799.
|
| [11] |
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology-Melanoma: cutaneous, version 1.2020[EB/OL]. (2020)[2021-08-19].
URL
|
| [12] |
Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993[J]. J Clin Oncol, 1999, 17(7): 2105-2116. DOI: 10.1200/JCO.1999.17.7.2105.
|
| [13] |
|
| [14] |
Zaremba A, Zimmer L, Griewank KG, et al. Immuntherapie beim malignen melanom(immunotherapy for malignant melanoma)[J]. Internist (Berl), 2020, 61(7): 669-675. DOI: 10.1007/s00108-020-00812-1.
|
| [15] |
Ralli M, Botticelli A, Visconti IC, et al. Immunotherapy in the treatment of metastatic melanoma: current knowledge and future directions[J]. J Immunol Res, 2020, 2020: 1-12. DOI: 10.1155/2020/9235638.
|
| [16] |
Quéreux G, Wylomanski S, Bouquin R, et al. Are checkpoint inhibitors a valuable option for metastatic or unresectable vulvar and vaginal melanomas？[J]. J Eur Acad Dermatol Venereol, 2018, 32(1): 39-40. DOI: 10.1111/jdv.14486.
|
| [17] |
Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage Ⅲ melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial[J]. Lancet Oncol, 2015, 16(5): 522-530. DOI: 10.1016/S1470-2045(15)70122-1.
|
| [18] |
Schiavone MB, Broach V, Shoushtari AN, et al. Combined immunotherapy and radiation for treatment of mucosal melanomas of the lower genital tract[J]. Gynecol Oncol Rep, 2016, 16(4): 42-46. DOI: 10.1016/j.gore.2016.04.001.
|
| [19] |
Indini A, Di Guardo L, Cimminiello C, et al. Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience[J]. J Gynecol Oncol, 2019, 30(6): 94-101. DOI: 10.3802/jgo.2019.30.e94.
|
| [20] |
Chanal J, Kramkimel N, Guegan S, et al. Locally advanced unresectable vaginal melanoma: response with anti-programmed death receptor 1[J]. J Low Genit Tract Dis, 2016, 20(1): e4-e5. DOI: 0.1097/LGT.0000000000000168.
|
| [21] |
Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation[J]. N Engl J Med, 2015, 372(4): 320-330. DOI: 10.1056/NEJMoa1412082.
|
| [22] |
Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma[J]. N Engl J Med, 2015, 372(26): 2521-2532. DOI: 10.1056/NEJMoa1503093.
|
| [23] |
Luke JJ, Rutkowski P, Queirolo P, et al. Pembrolizumab versus placebo after complete resection of high-risk stage Ⅱ melanoma: efficacy and safety results from the KEYNOTE-716 double-blind phase Ⅲ trial[J]． Ann Oncol, 2021, 32(suppl_5): S1283-S1346. DOI: 10.1016/annonc/annonc741.
|
| [24] |
Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma[J]. N Engl J Med, 2017, 377(14): 1345-1356. DOI: 10.1056/NEJMoa1709684.
|
| [25] |
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)恶性黑色素瘤诊疗指南[M]. 北京： 人民卫生出版社， 2020: 1-142.
|
| [26] |
Hou JY, Baptiste C, Hombalegowda RB, et al. Vulvar and vaginal melanoma: a unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2 253 cases of non-gynecologic melanoma[J]. Cancer, 2017, 123(8): 1333-1344. DOI: 10.1002/cncr.30473.
|
| [27] |
Komatsu-Fujii T, Nomura M, Otsuka A, et al. Response to imatinib in vaginal melanoma with KIT p．Val559Gly mutation previously treated with nivolumab, pembrolizumab and ipilimumab[J]. J Dermatol, 2019, 46(6): 203-204. DOI: 10.1111/1346-8138.14763.
|
| [28] |
Si L, Kong Y, Xu X, et al. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort[J]. Eur J Cancer, 2012, 48(1): 94-100. DOI: 10.1016/j.ejca.2011.06.056.
|
| [29] |
Kim G, McKee AE, Ning YM, et al. FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation[J]. Clin Cancer Res, 2014, 20(19): 4994-5000. DOI: 10.1158/1078-0432.CCR-14-0776.
|
| [30] |
McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomized, open-label study[J]. Lancet Oncol, 2014, 15(3): 323-332. DOI: 10.1016/S1470-2045(14)70012-9.
|
| [31] |
Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma[J]. N Engl J Med, 2019, 381(7): 626-636. DOI: 10.1056/NEJMoa1904059.
|
| [32] |
Kim KB, Sosman JA, Fruehauf JP, et al. BEAM: a randomized phase Ⅱ study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma[J]. J Clin Oncol, 2012, 30(1): 34-41. DOI: 10.1200/JCO.2011.34.6270.
|
| [33] |
Sheng X, Yan X, Chi Z, et al. Axitinibin combination with toripalimab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic mucosal melanoma: an open-label phase Ⅰ B trial[J]. J Clin Oncol, 2019, 37(32): 2987-2999. DOI: 10.1200/JCO.19.00210.
|